>R&D >R&D in Takeda

R&D in Takeda

Takeda determines its R&D strategy based on the latest medical needs. By concentrating investment of management resources in the core therapeutic areas of Cardiovascular & Metabolic, Oncology, Central Nervous System, Immunology & Respiratory, General Medicine and Vaccine, Takeda strives to achieve leading innovation in medicine.


  •  

R&D News

Latest Publications of Takeda Research Laboratories

R&D At a Glance

Main R&D Facilities

Takeda Pharmaceuticals International, Inc. (Deerfield, U.S.)

Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda. ( São Jerônimo, Brazil)

Takeda Pharmaceuticals International Co.(Cambridge, MA, U.S.)

Takeda California, Inc. (San Diego, CA, U.S.)

Takeda Vaccines (Montana), Inc. (Bozeman, MT, U.S.)

Takeda Development Center Americas, Inc. (Deerfield, IL. U.S.)

Takeda Ventures, Inc. (Palo Alto, CA, U.S.)

Inviragen, Inc. (Fort Collins, CO, U.S.)

Takeda GmbH (Konstanz, Germany)

Takeda Pharma A/S (Roskilde, Denmark)

Takeda Cambridge Limited (Cambridge, U.K.)

Takeda Development Centre Europe Ltd. (London, U.K.)
Takeda (China) Holdings Co., Ltd. (Shanghai, China)
Guangdong Techpool Bio-Pharma Co., Ltd. (Guangzhou, China) 
Takeda Singapore Pte Limited (Singapore)

Takeda Development Center Asia, Pte. Ltd. (Singapore)

Inviragen (Singapore) Pte. Ltd. (Singapore)

Shonan Research Center (Fujisawa, Japan)
Takeda Development Center Japan(Osaka, Japan)
Takeda Bio Development Center Limited (Tokyo, Japan)
CMC Center (Osaka, Japan)

R&D Investment ¥324.3 billion (FY2012)
Royalty Income ¥45.2 billion (FY2012)
Core Therapeutic Areas Cardiovascular & Metabolic
Oncology
Central Nervous System
Immunology & Respiratory
General Medicine
Vaccine
R&D Pipeline Takeda discloses ethical drugs under development that have reached phase I or higher status